🔍

GLAXO - Glaxosmi. Pharma

📊 NSE: GLAXO 🏢 Pharmaceuticals - Multinational 📅 Last Updated: 12/13/2025 22:22

📢 Recent Corporate Announcements

GSK Pharma Authorizes Key Personnel for Materiality Disclosures under SEBI Regulation 30(5)

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 21 Apr 2026, 11:46 AM

GlaxoSmithKline Pharmaceuticals Limited has updated its list of authorized personnel responsible for determining the materiality of events or transactions for stock exchange disclosures. The authorized officials include the Managing Director, CFO, Company Secretary, and Head of Legal. This update is a mandatory compliance requirement under Regulation 30(5) of the SEBI (LODR) Regulations, 2015. The announcement is administrative in nature and does not impact the company's financial performance or strategic direction.

Authorized Managing Director Mr. Bhushan Akshikar and CFO Mr. Ronojit Biswas to determine event materiality.
Included Company Secretary Mr. Ajay Nadkarni and Head of Legal Mr. Amit Pandey in the authorized disclosure team.
The filing is made in compliance with SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
Provides contact details for all authorized personnel for regulatory transparency.

💡 This is a routine regulatory filing with no impact on the company's fundamentals. Investors should focus on upcoming earnings reports and product pipeline developments instead.

GSK India Appoints Vinay Subramanian as Commercial Head – Oncology

🟢 POSITIVE ⭐ 4/10

MANAGEMENT 📅 21 Apr 2026, 10:35 AM

GlaxoSmithKline Pharmaceuticals Limited has appointed Mr. Vinay Subramanian as the Commercial Head of its Oncology division and a member of the Senior Management Personnel, effective April 20, 2026. Mr. Subramanian brings over 24 years of experience in the pharmaceutical and medical technology sectors, having held leadership roles at Roche, GE Healthcare, and Pfizer. His expertise in immunotherapy and establishing Cancer Care Centers is expected to strengthen GSK's specialized healthcare portfolio. This move signals a strategic focus on expanding the company's oncology presence in the India and South Asia region.

Mr. Vinay Subramanian appointed as Commercial Head – Oncology effective April 20, 2026
Brings over 24 years of experience in Pharmaceuticals, Life Science, and Medical Technology
Previously served as India Enabling leader at Roche Products India managing the immunotherapy portfolio
Past leadership experience includes significant roles at GE Healthcare, Becton Dickinson, and Pfizer
Holds an MBA and completed executive programs at UC Berkeley-Haas School of Business

💡 Investors should monitor the growth and revenue contribution of the oncology segment in upcoming quarters as the new leadership takes charge. This appointment is a positive indicator of GSK's commitment to high-growth specialized therapy areas.

GSK Pharma Submits SEBI Regulation 74(5) Compliance Certificate for Q4 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Apr 2026, 10:45 AM

GlaxoSmithKline Pharmaceuticals Limited has filed its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations for the period ending March 31, 2026. The document, provided by registrar KFin Technologies, confirms that all dematerialization requests were handled according to regulatory timelines. Specifically, it verifies that share certificates were cancelled and the register of members was updated within 30 days. This filing is a standard procedural requirement for listed companies in India to ensure the integrity of electronic shareholding.

Quarterly compliance certificate issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Covers the reporting period for the quarter ended March 31, 2026.
Confirms that securities received for dematerialization were processed and listed on stock exchanges.
Physical security certificates were mutilated and cancelled within the mandated 30-day period.
Registrar KFin Technologies Limited confirmed the substitution of depository names in the register of members.

💡 This is a routine administrative update with no impact on company fundamentals; investors should continue to monitor the company's operational performance and upcoming financial results.

GSK Pharma Shareholders Approve Ronojit Biswas as Director and CFO with Over 99% Votes

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 08 Apr 2026, 11:27 PM

GlaxoSmithKline Pharmaceuticals Limited has announced the successful passage of two ordinary resolutions via postal ballot. Shareholders overwhelmingly approved the appointment of Mr. Ronojit Biswas as a Director and as a Whole-time Director & Chief Financial Officer (CFO). Both resolutions received over 99.6% approval from the total votes cast, indicating strong shareholder confidence. The promoter group, which holds a significant stake, voted entirely in favor of the appointments.

Appointment of Mr. Ronojit Biswas as Director approved with 99.69% of valid votes cast.
Appointment of Mr. Ronojit Biswas as Whole-time Director & CFO approved with 99.76% of valid votes cast.
Total voter turnout represented 84.04% of the total outstanding shares, with 142.37 million votes polled.
Promoter and Promoter Group (127.05 million shares) voted 100% in favor of both resolutions.
Public institutional support was high, with over 97% of institutional votes cast in favor of the appointments.

💡 This is a routine management update confirming the formalization of the CFO's role. Investors should continue to monitor the company's financial execution under the confirmed leadership.

GSK Pharma Receives TDS Tax Demand of Rs 2.01 Crore for AY 2020-21

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 31 Mar 2026, 05:01 PM

GlaxoSmithKline Pharmaceuticals has received a tax demand order from the TDS Authority amounting to Rs 2.01 Crores for Assessment Year 2020-2021. The total liability consists of a TDS component of Rs 1.11 Crore and an interest component of Rs 0.90 Crore. The company maintains that there is no immediate impact on its financial statements as it is in the process of contesting the order. GSK Pharma will be filing an appeal before the relevant appellate authority to challenge the assessment.

Total tax demand liability of Rs 2.01 Crores issued by TDS Authority
Demand includes Rs 1.11 Crore in TDS and Rs 0.90 Crore in interest for AY 2020-21
Company is contesting the assessment order and filing an appeal
No immediate impact on financial statements as per the company's disclosure

💡 This is a minor tax matter with low financial materiality relative to the company's size; investors should treat this as a routine update and no action is required.

GSK Pharmaceuticals to Close Trading Window from April 1, 2026, for Q4 FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Mar 2026, 03:11 PM

GlaxoSmithKline Pharmaceuticals Limited has announced the closure of its trading window starting April 1, 2026, in compliance with SEBI Insider Trading Regulations. The closure is ahead of the declaration of the audited financial results for the fourth quarter and the full year ending March 31, 2026. The trading window will remain closed until 48 hours after the results are officially announced. The specific date for the Board Meeting to approve these results will be communicated at a later date.

Trading window for GSK shares to close effective Wednesday, April 1, 2026.
Closure pertains to the Audited Financial Results for the quarter and year ended March 31, 2026.
Window will reopen 48 hours after the announcement of the financial results.
Board meeting date for the result declaration is yet to be announced by the company.

💡 This is a routine regulatory filing for insider trading prevention and does not impact the company's fundamentals. Investors should monitor for the upcoming board meeting date to prepare for the Q4 and FY26 earnings release.

GSK Pharma CFO Juby Chandy Resigns to Take Global Role Effective March 11, 2026

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 16 Mar 2026, 06:00 PM

GlaxoSmithKline Pharmaceuticals Limited has announced the resignation of Mr. Juby Chandy from his dual roles as Whole-Time Director and Chief Financial Officer. The resignation became effective at the close of business hours on March 11, 2026. This management change is driven by Mr. Chandy's internal promotion to Finance Head for the Asia Pacific region within the global GSK group. The company had previously notified the exchanges of this transition on March 2, 2026.

Mr. Juby Chandy resigned as CFO and Whole-Time Director effective March 11, 2026
Transition is due to his new appointment as Finance Head for the Asia Pacific region at GSK
The official resignation letter was submitted to the Board on March 2, 2026
The company confirmed compliance with Regulation 30 of SEBI Listing Regulations
Mr. Chandy (DIN: 09530618) had served as a key member of the executive leadership team

💡 Investors should watch for the announcement of a new CFO to ensure continuity in financial strategy. Since this is an internal group promotion, it is unlikely to signal any underlying operational issues.

GSK Pharma to Appoint Ronojit Biswas as Whole-time Director & CFO for 3-Year Term

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 07 Mar 2026, 05:34 PM

GlaxoSmithKline Pharmaceuticals Limited has initiated a postal ballot to seek shareholder approval for the appointment of Mr. Ronojit Biswas as a Whole-time Director and Chief Financial Officer. The proposed tenure is for three years, effective from April 1, 2026, to March 31, 2029. Shareholders can participate in the electronic voting process from March 9 to April 8, 2026, with final results expected by April 10, 2026. This leadership change is part of the company's planned management transition.

Appointment of Mr. Ronojit Biswas as Whole-time Director and CFO for a 3-year term starting April 1, 2026.
E-voting period for shareholders is scheduled from March 9, 2026, to April 8, 2026.
The cut-off date for determining shareholder eligibility for voting was February 27, 2026.
The results of the postal ballot will be officially announced on or before April 10, 2026.

💡 Investors should take note of the leadership transition and monitor the official announcement of voting results on April 10, 2026. No immediate portfolio action is required as this is a standard management appointment.

GSK Pharma to Appoint Ronojit Biswas as WTD & CFO for 3-Year Term

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 07 Mar 2026, 05:30 PM

GlaxoSmithKline Pharmaceuticals Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Mr. Ronojit Biswas as a Whole-time Director and Chief Financial Officer. The proposed appointment is for a period of three years, effective from April 1, 2026, to March 31, 2029. Shareholders can participate in the decision via remote e-voting, which is scheduled to take place between March 9 and April 8, 2026. The results of the ballot will be declared on or before April 10, 2026.

Appointment of Mr. Ronojit Biswas as Whole-time Director and CFO for a 3-year term starting April 1, 2026
Remote e-voting period scheduled from March 9, 2026, to April 8, 2026
Cut-off date for determining shareholder voting eligibility was February 27, 2026
Final results of the postal ballot to be announced by April 10, 2026

💡 This is a routine leadership appointment; investors should monitor the voting results for confirmation of the new CFO's tenure but no immediate action is required.

GSK Pharma Receives GST Demand of Rs 6.93 Crore for Alleged Non-Payment on Exports

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 07 Mar 2026, 10:42 AM

GlaxoSmithKline Pharmaceuticals Limited has received a tax demand order from the Maharashtra GST authorities totaling Rs. 6.93 crore. The demand, pertaining to the period April 2022 to March 2023, includes a tax component of Rs. 3.46 crore and an equivalent penalty of Rs. 3.46 crore. The issue relates to alleged non-payment of GST on the export of services. The company has stated that this development will not impact its financial operations and it will take appropriate legal actions.

Total demand of Rs. 6,92,76,478 raised by the Additional Commissioner, CGST & Central Excise, Mumbai Central
Demand includes a tax amount of Rs. 3,46,38,239 and a penalty of Rs. 3,46,38,239
The dispute concerns alleged GST liability on the export of services for the FY 2022-23 period
Company received the physical order on February 20, 2026, and plans to challenge the demand

💡 Investors should view this as a routine regulatory matter with minimal impact on the company's overall valuation. No immediate action is required as the company intends to contest the demand.

GSK Pharma Appoints Ronojit Biswas as CFO and Whole-Time Director

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 02 Mar 2026, 12:20 PM

GlaxoSmithKline Pharmaceuticals has appointed Mr. Ronojit Biswas as its new Whole-Time Director and Chief Financial Officer for a three-year term starting April 1, 2026. He succeeds Mr. Juby Chandy, who will step down on March 11, 2026, to take on a senior regional role as APAC Finance lead within the GSK Group. Mr. Biswas is a company veteran with over 25 years of experience, having previously served as CFO for GSK's operations in Brazil and Vietnam. This transition represents a planned internal succession within the global GSK framework.

Mr. Ronojit Biswas appointed as CFO and Whole-Time Director for a 3-year term effective April 1, 2026.
Outgoing CFO Juby Chandy to transition to a new role leading APAC Finance within the GSK Group.
Mr. Biswas brings over 25 years of global experience with GSK, including leadership roles in Singapore, Brazil, and the UK.
The appointment was approved by the Board of Directors in a meeting held on March 2, 2026.

💡 Investors should monitor the transition but can take comfort in the appointee's extensive 25-year history with the parent group. No immediate impact on stock performance is expected from this routine internal leadership rotation.

GSK Pharma Appoints Ronojit Biswas as CFO; Juby Chandy to Transition to APAC Role

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 02 Mar 2026, 12:18 PM

GlaxoSmithKline Pharmaceuticals has announced the appointment of Mr. Ronojit Biswas as its new Whole-Time Director and Chief Financial Officer for a three-year term starting April 1, 2026. He replaces the current CFO, Mr. Juby Chandy, who will step down on March 11, 2026, to take on a senior leadership role as the head of APAC Finance within the GSK Group. Mr. Biswas is a GSK veteran with over 25 years of experience, having previously served as CFO for GSK's operations in Brazil and Vietnam. This transition reflects a planned internal succession strategy within the multinational's global framework.

Mr. Ronojit Biswas appointed as CFO and Whole-Time Director for a 3-year term effective April 1, 2026.
Outgoing CFO Juby Chandy to transition to a regional role leading APAC Finance for GSK Group after March 11, 2026.
Incoming CFO Ronojit Biswas brings 25+ years of experience, including previous CFO roles in Brazil and Vietnam.
Mr. Biswas most recently served as Senior Finance Director – Global Product Strategy, based in Singapore.
The leadership change was approved during a board meeting held on March 2, 2026.

💡 This is a routine leadership transition within a multinational corporation; investors should monitor if the new CFO introduces any shifts in capital allocation or cost-management strategies.

DRI Conducts Search at GlaxoSmithKline Pharmaceuticals' Mumbai Office Under Customs Act

🔵 WATCH ⭐ 6/10

REGULATORY 📅 28 Feb 2026, 04:07 PM

The Directorate of Revenue Intelligence (DRI) initiated a search at the registered office of GlaxoSmithKline Pharmaceuticals in Mumbai on February 27, 2026. The action was carried out under Section 105 of the Customs Act, 1962, and concluded on February 28, 2026. The company has stated that it extended full cooperation to the authorities and that its business operations continue as usual. While the specific allegations are not yet disclosed, the company reports no immediate quantifiable impact on its financial or operational activities.

Search conducted by the Directorate of Revenue Intelligence (DRI) at the Mumbai headquarters.
Action initiated under Section 105 of the Customs Act, 1962, relating to import/export regulations.
Search operation spanned two days, starting February 27 and concluding on February 28, 2026.
Company confirms business operations remain unaffected with no immediate financial impact reported.

💡 Investors should remain cautious and monitor for subsequent disclosures regarding the findings of the DRI search. Any potential tax liabilities or penalties arising from this investigation could impact future earnings.

GSK Pharma Q3 FY26: Revenue Crosses ₹1,000 Cr Milestone with 35.9% EBITDA Margin

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 16 Feb 2026, 05:04 PM

GlaxoSmithKline Pharmaceuticals reported a milestone quarter with revenue crossing ₹1,000 crores for the first time, achieving 10% consolidated growth. The company saw a significant EBITDA margin expansion of 520 basis points to 35.9%, driven by gross margin improvements and disciplined cost control. A major strategic shift is underway with the oncology foray, where the eligible patient pool for Jemperli expanded from 800 to 6,000 following regulatory approval for first-line endometrial cancer. The pediatric vaccine segment also maintained strong momentum with 11% growth during the quarter.

Quarterly revenue crossed the ₹1,000 crore mark for the first time with 8.1% standalone growth.
EBITDA margins improved by 520 basis points to 35.9% despite a ₹11.8 crore one-off labor cost impact.
Oncology target patient base increased to 6,000 following RUBY-1 trial approval for first-line endometrial cancer.
Pediatric vaccine portfolio grew by 11%, led by double-digit growth in Boostrix, Varilrix, and Havrix brands.
Strong liquidity position maintained with a cash balance of ₹2,426 crores as of Q3 FY2026.

💡 Investors should note the successful margin expansion and the strategic pivot toward high-value specialty oncology and adult vaccines. The significant increase in the addressable patient pool for new launches suggests a positive outlook for long-term revenue diversification.

GSK Pharmaceuticals Releases Recording of Analyst and Institutional Investor Meeting

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Feb 2026, 04:23 PM

GlaxoSmithKline Pharmaceuticals Limited has officially shared the video recording link of its recent Analyst and Institutional Investor meeting held in February 2026. This disclosure is a mandatory compliance requirement under Regulation 30 of the SEBI (LODR) Regulations, 2015. The recording allows the broader investor community to access the same information and management commentary provided to institutional participants. Such interactions typically provide deeper insights into the company's strategic outlook and operational performance.

Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Recording of the Analyst/Institutional Investor meeting made available via the company's official website.
The filing was submitted to both BSE and NSE on February 11, 2026.
Provides transparency regarding management's discussions with institutional stakeholders.

💡 Investors should review the recording on the company's website to understand management's views on growth and the product pipeline. No immediate action is required as this is a routine regulatory filing.

View All GLAXO Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Standalone revenue for Q2 FY26 was INR 974 Cr, a decline of 2.6% YoY. Pediatric vaccines grew by 13% YoY, while the adult vaccine (Shingrix) also saw double-digit growth. General Medicines business was flattish/declined due to a combined INR 70-75 Cr impact from supply issues and GST reforms.

Geographic Revenue Split

Not disclosed in available documents, though the company operates primarily in the Indian Pharmaceutical Market (IPM) with exports mentioned as an industry-wide factor.

Profitability Margins

Gross margins improved and are expected to be sustainable due to stable raw material prices. Net Profit After Tax (before exceptional items) for Q2 FY26 was INR 253 Cr, representing a 26.1% margin, which is a 150 bps improvement YoY.

EBITDA Margin

EBITDA margin reached 34.4% in Q2 FY26, a significant improvement of 250 basis points YoY, driven by cost savings, better product mix, and field cost productivity.

⚙️ Operational Drivers

Raw Materials

Specific chemical names not listed; however, raw materials are noted as having 'stable prices' with no current spikes, allowing for sustained gross margins.

Key Suppliers

The company relies on third-party Contract Manufacturing Organizations (CMOs). One specific CMO (unnamed) suffered a fire incident that caused a supply disruption.

Capacity Expansion

Not disclosed in available documents; however, the company is focusing on 'product transformation' by launching innovative assets like Jemperli and Zejula.

Raw Material Costs

Raw material costs are described as stable. The company focuses on expanding gross margins through a singular focus on cost consciousness and mitigating input cost fluctuations.

Manufacturing Efficiency

Field cost productivity has been maintained. The company is moving toward high-category growth innovative assets to improve overall profitability.

📈 Strategic Growth

Expected Growth Rate

10%+

Growth Strategy

Growth will be driven by the launch of the Oncology portfolio (Jemperli and Zejula), scaling of Specialty brands (Nucala, Trelegy), and double-digit growth in the Vaccine segment (Shingrix). The company aims to recover from Q2 headwinds to meet its double-digit ambition for the full year.

Products & Services

Pharmaceutical products including anti-infectives, pain medications, dermatologicals, oncology drugs (Jemperli, Zejula), and vaccines (Shingrix, pediatric vaccines).

Brand Portfolio

Calpol, Nucala, Trelegy, Shingrix, Jemperli, Zejula.

New Products/Services

Launched Oncology portfolio on August 15, 2025, featuring Jemperli (for endometrial cancer) and Zejula (for ovarian cancer). These are expected to contribute significantly in coming quarters.

Market Expansion

Focusing on Gyn-Oncology solutions for Indian patients and expanding the adult vaccination market through Shingrix.

Market Share & Ranking

Maintained a competitive market share of approximately 27.6% in relevant segments.

🌍 External Factors

Industry Trends

The industry is shifting toward specialty medicines and oncology. There is an increasing threat from generics and biosimilars due to patent expirations and India's strong generic export position.

Competitive Landscape

Faces competition from generic drug manufacturers and other multinational pharma companies in the acute and specialty segments.

Competitive Moat

Moat is built on strong brand equity (e.g., Calpol), a leadership position in vaccines, and a strategic shift toward high-margin, innovative specialty drugs that are harder to commoditize.

Macro Economic Sensitivity

The acute segment of the Indian Pharmaceutical Market (IPM) grew below 5% in Q2, indicating sensitivity to seasonal demand and overall market softness.

Consumer Behavior

Increased demand for adult vaccines (Shingrix) and specialized oncology treatments as patient awareness and diagnostic capabilities improve.

Geopolitical Risks

Global geopolitical tensions are cited as factors that disrupt supply chains and increase raw material cost volatility.

⚖️ Regulatory & Governance

Industry Regulations

Strict pricing regulations under the National List of Essential Medicines (NLEM) impact profit margins. Manufacturing must meet high GSK global quality standards.

Taxation Policy Impact

Impacted by GST reforms which had a transitionary revenue impact of INR 30-32 Cr in Q2 FY26.

Legal Contingencies

The company is evaluating a demand order (value not specified) and plans to take appropriate legal actions. No other specific court case values were disclosed.